focus -WSS

focus

author：entertainment 2025-10-01 23:03:39 - browse：98

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

WSS

Life science postdocs should get big pay hike, NIH panel says

Fauci's latest grilling in Congress: 9 hours, behind closed doors

What to watch for from Zogenix and Amicus clinical trials

The haunting brain science of long Covid

Physician assistants need a new name. Here's what it should be

Profiling embryos to choose those with higher IQs is almost a reality

focus

focus

focus

某新三板公司，2015年初挂牌新三板，2015年6月开始做市。

A new crop of companies is reshaping the health data economy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

New lawsuit accuses health insurer Cigna of denying claims in bulk

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UHS says company favors patients whose insurance pays more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

American taxpayers paid $1.8 trillion in health care costs in 2022

Hepatitis C has a cure — but many Americans still lack access to it

New Alzheimer's drugs heat up race for early detection blood tests

hotspot

Why patients can’t get everything they want on drug pricing

Merck to acquire Harpoon Therapeutics for $680 million

Medicare Advantage coverage denials need scrutiny, senators say

Merck to acquire Harpoon Therapeutics for $680 million

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

hotspot

hotspot

focus